Dr. Reddy’s Holds 98.6% Of The Shares In OctoPlus After The Post Closing Acceptance Period

This is a joint press release by Reddy Netherlands B.V. (the “Offeror”), a wholly owned subsidiary of Dr. Reddy's Laboratories Ltd. (“Dr. Reddy's”), Dr. Reddy’s and OctoPlus N.V. (“OctoPlus” or the “Company”) pursuant to Section 17, paragraph 4 of the Dutch Public Takeover Decree ( Besluit openbare biedingen Wft, the “Decree”) in connection with the recommended public offer (the “Offer”) by the Offeror for all the issued and outstanding ordinary shares in the capital of OctoPlus (the “Shares”).

This press release does not constitute, or form part of, an offer or any solicitation of an offer, to acquire or subscribe or sell any securities in OctoPlus. The Offer is only made by means of the Offer Memorandum (as defined below). This announcement is not for release, publication, dissemination, or distribution, in whole or in part, in or into Canada and Japan. Capitalised terms not defined in this press release shall have the meaning given thereto in the Offer Memorandum.

With reference to the joint press releases of Dr. Reddy’s (NYSE: RDY) and OctoPlus (NYSE Euronext Amsterdam: OCTO), issued on 22 October 2012, 13 December 2012 and 12 February 2013, respectively, the Offeror and OctoPlus hereby jointly announce that the Offeror holds 98.6% of the Shares after the Post Closing Acceptance Period.

Results Post Closing Acceptance Period

During the Post Closing Acceptance Period, which ended at 18.00 hours CET on 26 February 2013, 2,746,658 Shares, representing 5.2% of the Shares and a value of EUR 1,428,262.16, have been tendered for acceptance under the Offer. 1

As a result the Offeror’s shareholding is composed as follows:
        Number of Shares                     Percentage of Shares
Shares tendered under the Post Closing Acceptance Period       2,746,658                     5.2%
Shares acquired during the Post Closing Acceptance Period       387,750                     0.7%
Shares tendered and acquired by the Offeror during the Offer Period       48,808,638                     92.7%
Total Shares tendered and acquired       51,943,046                     98.6%

The 48,808,638 Shares held by the Offeror at the end of the Offer Period, together with the Shares tendered under the Post Closing Acceptance Period and the Shares acquired during under the Post Closing Acceptance Period, represent a total of 98.6% of the Shares.

If you liked this article you might like

Generics Drop Across Board as DOJ Inquiry Expands

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

Changing Landscape for Generic-Drug Makers Creates Opportunities

Dr Reddy's Laboratories (RDY) Highlighted As Weak On High Volume

Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tomorrow: GLV, GLO, RDY